[Fraxiparin as a component of lymphotropic polychemotherapy of locally spread valvular cancer in patients with chronic venous insufficiency].
A total of 29 female patients with locally spread cancer of the vulva in chronic venous insufficiency underwent lymphotropic polychemotherapy. Of these, 16 subjects (55.2%) had varicosis, 13 (44.8%) presented with chronic thrombophlebitis. All above patients were found to run a high risk for development of thromboembolic complications. Administration of the thrombolytic-complication prophylaxis is exercised through the use of fraxiparin, a drug of choice. With lymphotropic polychemotherapy instituted in patients with locally spread carcinoma of the vulva and chronic venous insufficiency, fraxiparin ("Sanofi-Synthelabo") proved to be a highly effective means of prophylaxis against thromboembolic complications.